welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
John L. Jefferies, MD, MPH, FACC, FAHA, FHFSA
University of Tennessee Health Science Center
A312 Coleman Building
956 Court Avenue
Memphis, Tennessee, United States
In 2018, John L. Jefferies has been appointed the Jay M. Sullivan Endowed Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center (UTHSC). He has also been named co-director for UT Methodist Institute for Cardiovascular Science.
Dr. Jefferies graduated from UT Knoxville with a degree in microbiology in 1992 and acquired his medical degree from UTHSC in 1996. He then completed an internship and residency in internal medicine and pediatrics at the University of Kentucky followed by adult and pediatric cardiology (combined) training at Baylor College of Medicine in Houston, TX. Dr. Jefferies has served for more than eight years at the University of Cincinnati College of Medicine and Cincinnati Children’s, where he was an associate professor of adult cardiovascular disease and pediatric cardiology from 2010-2015, professor of adult cardiovascular disease and pediatric cardiology from 2015-2018, and professor of human genetics from 2015-2018.
His research interests include novel gene discovery for various forms of cardiomyopathy, quality-of-life research in cardiomyopathy and heart failure, cardio-oncology, cardiac care in genetic syndromes, and novel drug investigation in heart failure.
other Duchenne content
Modelling Duchenne Muscular Dystrophy in MYOD1-Converted Urine-Derived Cells Treated With 3-Deazaneplanocin A Hydroc...Duchenne muscular dystrophy (DMD) is a s...
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a multicenter, open-label, long-...
Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dy...Duchenne/Becker muscular dystrophy (DMD/...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Nicolas S. Wein, PhDDr. Nicolas S. Wein is a Principal Inves...
Pier Lorenzo Puri, MD, PhDPier Lorenzo Puri earned his M.D. at the...
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
Duchenne and Becker Muscular Dystrophy BasicsMuscular dystrophies are a group of gene...